Enrollment of PR+ ovarian cancer trial on track, initial data in 2020
Program update on onapristone ER in hormone positive breast cancer
PHILADELPHIA–(BUSINESS WIRE)–#ASCO–Context Therapeutics, a clinical-stage biopharmaceutical company dedicated to advancing medicines for hormone driven cancers, today announced that chief executive officer Martin Lehr will deliver a corporate presentation at Biotech Showcase™ 2020, being held January 13-15, 2020, at the Hilton San Francisco Union Square in San Francisco.
During the presentation, Mr. Lehr will provide updates on Context’s lead clinical program, onapristone extended release (onapristone ER), including the Company’s ongoing Phase 2 study (ONWARD 220) evaluating onapristone ER alone in patients with progesterone receptor positive (PR+) rare ovarian and endometrial cancers, and pending combination trials in ER+,PR+,HER2- breast cancer.
Details for this presentation are as follows:
Time/Date: 4:30 p.m. PT on Tuesday, January 14, 2020
Location: Hilton San Francisco Union Square
Room: Franciscan D (Ballroom Level)
To schedule a meeting with the Context management team, please email [email protected].
About Onapristone ER
Onapristone ER (onapristone extended release) is a potent and specific antagonist of the progesterone receptor that is orally administered. Currently, there are no approved therapies that selectively target PR+ cancers. Preliminary preclinical and clinical data suggest that onapristone ER has anticancer activity by inhibiting progesterone receptor binding to chromatin, downregulating cancer stem cell mobilization and blocking immune evasion. Onapristone ER is currently the subject of an ongoing Phase 2 clinical trial in progesterone receptor positive ovarian cancer. Additional Phase 2 clinical trials in breast and endometrial cancers will initiate in 2020. Onapristone ER is an investigational drug that has not been approved for marketing by any regulatory authority.
About Context Therapeutics®
Context Therapeutics LLC is a clinical-stage biopharmaceutical company advancing medicines to treat hormone driven cancers. Context’s lead program is onapristone ER, an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) breast, ovarian and endometrial cancers. For more information on Context, visit www.contexttherapeutics.com.
Co-Founder & Chief Executive Officer